Your browser doesn't support javascript.
Oral isotretinoin treatment in patients with acne vulgaris during the COVID-19 pandemic: A retrospective cohort study in a tertiary care hospital.
Demirel Ögüt, Neslihan; Kutlu, Ömer; Erbagci, Ece.
  • Demirel Ögüt N; Department of Dermatology and Venereology, Usak University Training and Research Hospital, Usak, Turkey.
  • Kutlu Ö; Department of Dermatology and Venereology, School of Medicine, Usak University, Usak, Turkey.
  • Erbagci E; Department of Dermatology and Venereology, Usak University Training and Research Hospital, Usak, Turkey.
J Cosmet Dermatol ; 20(7): 1969-1974, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1197160
ABSTRACT

BACKGROUND:

Patients with acne vulgaris continue to present increasingly in dermatology outpatient clinics and seek treatment during the COVID-19 pandemic. As far as we know, the effect of isotretinoin on COVID-19 has not been studied before.

AIM:

We aimed to evaluate whether patients receiving oral isotretinoin are at increased risk of COVID-19 infection by comparing them with patients on topical treatment for acne vulgaris.

METHODS:

The data were collected retrospectively from a cohort of 267 acne vulgaris patients, who were under follow-up for acne vulgaris treatment during the pandemic period.

RESULTS:

Total of 227 patients (141 receiving isotretinoin treatment and 86 receiving topical treatment) were included of whom 29 patients had COVID-19 infection during acne vulgaris treatment. Fifteen (10.6%) patients were receiving oral isotretinoin and 14 (16.3%) were receiving topical acne treatment at the time of COVID-19 infection. The mean cumulative dose was 2340 ± 1988 mg at the time of COVID-19 infection. The mean elapsed time between the onset of isotretinoin treatment and positive PCR result for COVID-19 was 13.3 ± 10.3 weeks. Nine patients (64.3%) receiving isotretinoin treatment and 9 patients (60%) under topical treatment had loss of taste and smell during COVID-19 infection. Isotretinoin treatment was not found to be associated with a significant increased risk of getting COVID-19 (odds ratio, 0.671; 95% confidence interval, 0.247-1.823; P  = 0.434).

CONCLUSION:

As a conclusion, the results of this study encourage dermatologists and acne vulgaris patients to initiate oral isotretinoin treatment safely during the pandemic period.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Acne Vulgaris / Dermatologic Agents / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: J Cosmet Dermatol Journal subject: Dermatology Year: 2021 Document Type: Article Affiliation country: Jocd.14168

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Acne Vulgaris / Dermatologic Agents / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: J Cosmet Dermatol Journal subject: Dermatology Year: 2021 Document Type: Article Affiliation country: Jocd.14168